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Summary
Background Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity 
and mortality remain high in sub-Saharan Africa. Identiﬁ cation and treatment of asymptomatic people with chronic 
HBV infection should reduce the disease burden. We therefore assessed the feasibility of a screen-and-treat 
programme for HBV infection in The Gambia, west Africa, and estimated the proportion of HBV-infected people who 
had  signiﬁ cant liver disease in need of treatment.
Methods Between Dec 7, 2011, and Jan 24, 2014, individuals living in randomly selected communities in western 
Gambia were oﬀ ered hepatitis B surface antigen (HBsAg) screening via a point-of-care test. The test was also oﬀ ered 
to potential blood donors attending the central hospital in the capital, Banjul. HBsAg-positive individuals were invited 
for a comprehensive liver assessment and were oﬀ ered treatment according to international guidelines. We deﬁ ned 
linkage to care as visiting the liver clinic at least once. Eligibility for treatment was judged in accordance with the 2012 
European Association for the Study of the Liver guidelines.
Findings HBsAg screening was accepted by 5980 (weighted estimate 68·9%, 95% CI 65·0–72·4) of 8170 adults from 
27 rural and 27 urban communities and 5559 (81·4%, 80·4–82·3) of 6832 blood donors. HBsAg was detected in 495 (8·8%, 
7·9–9·7) individuals in communities and 721 (13·0%, 12·1–13·9) blood donors. Prevalence was higher in men 
(239 [10·5%, 8·9–12·1] of 2328 men vs 256 [7·6%, 6·5–8·7] of 3652 women; p=0·004) and middle-aged participants. 
Linkage to care was high in the communities, with 402 (81·3%) of 495 HBsAg-positive individuals attending the clinic. 
However, only 300 (41·6%) of 721 HBsAg-positive people screened at the blood bank linked into care. Of those who 
attended the clinic, 18 (4·4%, 2·5–7·7) patients from the communities and 29 (9·7%, 6·8–13·6) from the blood bank were 
eligible for treatment. Male sex was strongly associated with treatment eligibility (odds ratio 4·35, 1·50–12·58; p=0·007).
Interpretation HBV infection remains highly prevalent in The Gambia. The high coverage of community-based 
screening, good linkage into care, and the small proportion of HBsAg carriers who need treatment suggest that large-
scale screening and treatment programmes are feasible in sub-Saharan Africa.
Funding European Commission (FP7).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Hepatitis B virus (HBV) infection is highly prevalent in 
sub-Saharan Africa, where 80 million people are 
chronically infected with the virus.1 Hepatocellular 
carcinoma remains one of the most common cancers in 
the region and is mainly attributable to HBV.2 Hepatitis B 
vaccine coverage in sub-Saharan Africa is imperfect3 and 
many people born before the introduction of the vaccine 
continue to carry the virus, which confers a risk of 
cirrhosis and hepatocellular carcinoma.4
In 2015, WHO has published its ﬁ rst guidelines on 
chronic HBV infection, but the recommendations for 
sub-Saharan Africa are very limited due to insuﬃ  cient 
data.5 In sub-Saharan Africa, screening and treatment for 
hepatitis B are rarely accessible6,7 and blood banks are the 
only places where people are oﬀ ered free HBV testing. 
However, these free tests are to ensure the safety of the 
blood products, and deferred donors are rarely linked to 
care.8 Although the prevalence of infection is high in the 
general population in sub-Saharan Africa,9 people have 
very little opportunity to be tested for HBV unless they 
are infected with HIV or develop advanced liver disease. 
Screening and treatment interventions that target the 
general population have never been assessed in 
sub-Saharan Africa.
Prevention of Liver Fibrosis and Cancer in Africa 
(PROLIFICA), the ﬁ rst screen-and-treat programme for 
HBV mono-infected people in sub-Saharan Africa, was 
started in June, 2011, in The Gambia, west Africa.10 As 
part of this programme, we investigated whether mass 
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screening for HBV infection is justiﬁ ed by referring to 
the Wilson and Jungner WHO criteria for disease 
screening.11 We previously reported that hepatitis B 
surface antigen (HBsAg) point-of-care tests perform well 
in ﬁ eld conditions in the African community setting.12 
We validated inexpensive and simple diagnostic tools for 
the assessment of liver disease.13 We also identiﬁ ed risk 
factors for liver disease progression by following up a 
population-based cohort in rural Gambia.14
In this study, we assessed the acceptability and 
feasibility of a screen-and-treat HBV intervention 
programme in west Africa by analysing screening 
coverage, prevalence of HBsAg, the proportion of 
HBsAg-positive individuals linked to care, and the 
proportion of chronically infected people with clinically 
signiﬁ cant liver disease in need of treatment in 
community-based and facility (blood bank)-based 
settings in The Gambia.
Methods
Community screening
We did the community-based screening in the western 
part of The Gambia (ﬁ gure 1) where 750 000 people live 
in 1450 census enumeration areas deﬁ ned by the Gambia 
Bureau of Statistics. We used enumeration area as a 
sampling unit, and one enumeration area can consist of 
an entire village, part of a large village or town, or a 
cluster of small hamlets. Because HBV prevalence might 
diﬀ er between urban and rural populations, we ﬁ rst 
stratiﬁ ed the 1450 enumeration areas into urban (n=1197) 
and rural (n=253) communities. Then, we selected 
27 enumeration areas from each stratum by simple 
random sampling with a random number generator 
(Stata). In the selected enumeration areas, all inhabitants 
aged 30 years or older were eligible for screening. We 
excluded people younger than 30 years because the 
national hepatitis B vaccination programme started in 
1990 so these people should be covered.15 We organised a 
meeting in each enumeration area with the help of the 
village head. After community approval was obtained, a 
team of ﬁ eldworkers did a census by visiting all 
households to register the name, age, and sex of all 
eligible people and to invite them for screening. Pre-test 
counselling was delivered and written consent obtained. 
Ethics approval for the study was granted by the 
Government of The Gambia and MRC Gambia Joint 
Ethics Committee.
We did ﬁ nger-prick whole blood test for HBsAg using a 
point-of-care test (Determine, Alere, Waltham, MA, 
USA), the performance of which has been validated in 
the ﬁ eld (sensitivity 88·5%, speciﬁ city 100%).12 We 
provided the results to the participants on site with post-
test counselling, and those who tested positive for HBsAg 
were referred to the liver clinic at the Medical Research 
Council (MRC) unit in Fajara (ﬁ gure 1). People who were 
invited, but did not attend screening were reminded 
by the ﬁ eldworkers up to three times. Reasons for 
non-attendance to the screening were captured 
in a standardised form. Additional questions about 
knowledge of HBV infection and past experience of HBV 
testing were administered to all individuals screened 
between Aug 18 and Nov 1, 2013.
Facility-based screening
Since 2011, in addition to HIV testing, the Edward 
Francis Small Teaching Hospital (EFSTH), the only 
tertiary care hospital in Banjul, the capital of The Gambia, 
started HBV screening at its blood bank by use of a point-
of-care test (Onsite Combo Rapid Test, CTK Biotech, 
San Diego, CA, USA). The manufacturer of the test 
reports its sensitivity to be 96% and its speciﬁ city to be 
100%. Blood donors at the EFSTH blood bank must be 
healthy and aged at least 16 years. Individuals who tested 
positive for HBsAg were referred to a study nurse posted 
at EFSTH who provided post-test counselling and 
advised them to visit the MRC clinic in Fajara. Individuals 
who were co-infected with HIV and HBV were referred 
to the national HIV programme.
Research in context
Evidence before this study
We searched MEDLINE and Embase for articles written in French 
or English and published before Sept 1, 2015, with terms 
incorporating “hepatitis B”, “mass screening”, and “Africa”. We 
were unable to ﬁ nd any previous studies describing screen-and-
treat interventions for hepatitis B virus (HBV) infection that 
targeted the general population in Africa.
Added value of this study
To our knowledge, PROLIFICA is the ﬁ rst screen-and-treat 
intervention programme to be implemented in Africa. In 
addition to showing the feasibility of such an intervention, our 
results provide new data on screening coverage for HBV 
testing, the prevalence of hepatitis B surface antigen positivity, 
linkage of screening to health care, and the proportion of 
chronically infected people with clinically signiﬁ cant liver 
disease who need treatment.
Implications of all the available evidence
By providing further evidence for the high prevalence of HBV 
infection and the good coverage achieved with HBV screening 
and care, our results show the feasibility of a large-scale 
screen-and-treat programme for HBV infection in The Gambia. 
This approach deserves to be assessed in other resource-limited 
HBV-endemic countries. National health departments in 
sub-Saharan Africa and WHO should consider integrating such a 
programme into public health strategies to ﬁ ght against the 
epidemic of HBV infection in Africa. 
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Linkage to care
In individuals who tested positive for HBsAg in both the 
community-based and facility-based screening, linkage 
to care was deﬁ ned as visiting the outpatient PROLIFICA 
liver clinic at least once after HBV screening. Those who 
did not come to the clinic were reminded up to three 
times via telephone calls from the ﬁ eldworkers. We used 
semi-structured interviews in a subgroup of HBsAg-
positive participants (all individuals screened between 
Aug 1 and Nov 30, 2013) to identify reasons for non-
attendance to the clinic.
Assessment of liver disease
Patients who attended the liver clinic underwent a 
standardised comprehensive liver assessment that included 
physical examination, abdominal ultrasound (Portable 
MyLab25Gold, Esaote, Cambridge, UK), fasting liver 
stiﬀ ness measurement with hepatic transient elastography 
(Fibroscan 402, Echosens, Paris, France),16 and routine 
serum haematology and biochemistry tests. Optimum 
cutoﬀ  values for liver stiﬀ ness measurements were 
established previously by use of liver histology as a 
reference: the cutoﬀ  for clinically signiﬁ cant ﬁ brosis was 
7·9 kPa (Metavir score ≥F2) and the cutoﬀ  for cirrhosis was 
9·5 kPa (F4).13 Liver stiﬀ ness measurements were deemed 
unreliable if they had a ratio of IQR divided by liver stiﬀ ness 
measurement greater than 0·30 when liver stiﬀ ness 
measurement is at least 7·1 kPa.17 Blood samples were 
tested for hepatitis B envelope antigen (HBeAg; ELISA-
ETI-EBK Plus, Diasorin, Saluggia, Italy) and antibodies to 
hepatitis C virus (HCV; AxSYM, anti-HCV, Abbott, Chicago, 
IL, USA) and hepatitis delta virus (HDV; ETI-AB-
DELTAK-2, Diasorin). Antibodies to HIV-1 and HIV-2 were 
detected with an enzyme immunoassay (Genscreen 
ULTRA HIV Ag-Ab, Bio-Rad, Hercules, CA, USA). HBV 
DNA levels were measured with an in-house quantitative 
real-time polymerase chain reaction (qPCR) assay (lower 
limit of detection of 50 IU/mL), which was validated against 
commercial HBV qPCR assays (the COBAS TaqMan HBV 
Version 2.0 test on a COBAS AmpliPrep [Roche, Basel, 
Switzerland] and the Abbott Real Time HBV assay [Abbott 
Molecular Diagnostics, Wiesbaden, Germany]; r²=0·90 for 
correlation with the commercial assay).18 All blood samples 
were tested at the MRC unit in Fajara. Quality control and 
HBV genotyping were done by a reference laboratory in 
France (INSERM U1052, Lyon, France).
Antiviral therapy
HBsAg-positive individuals who attended the liver clinic 
were assessed for eligibility for treatment in accordance 
with the 2012 European Association for the Study of the 
Liver (EASL) guidelines19 (appendix p 3). In the absence 
of contraindications, tenofovir (tenofovir disoproxil 
fumarate) was provided free of charge (Viread [Gilead 
Sciences, Foster City, CA, USA], 300 mg oral dose once 
per day). Adherence to treatment was assessed with the 
Morisky adherence scale.20
Figure 1: Locations of the urban and rural community areas selected for screening
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Figure 2: Flow chart of study participants
*Other reasons for non-participation were too busy (n=65); feeling ill (n=55); husband refusal (women only; 
n=43); afraid of bleeding (n=21); no trust in Medical Research Council (n=11); already tested before (n=4); and 
refusal without revealing any speciﬁ c reason (n=157). †Estimates accounted for survey design. ‡Estimates 
accounted for survey design and non-attendance to the programme.  HBsAg=hepatitis B surface antigen.
Community screening Blood bank screening
8170 eligible for screening in 54 enumeration areas
 (Dec 7, 2011, to Jan 24, 2014)
2190 not screeened
 714 absent because of work or travel
 567 perceived no beneﬁt
 356 had other reasons*
 553 lost to follow-up
5980 (68·9%)† screened for HBsAg
495 (8·8%)‡ tested positive for HBsAg
402 (81·3%)‡ linked to care
18 (4·4%)‡ eligible for antiviral therapy
6832 eligible for screening at blood bank
 (Jan 1, 2013, to Dec 31, 2013)
5559 (81·4%) screened for HBsAg
721 (13·0%) tested positive for HBsAg
300 (41·6%) linked to care
29 (9·7%) eligible for antiviral therapy
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Statistical analysis
We estimated screening coverage for the enumeration 
areas included in the study by dividing the number of 
individuals screened by the population according to the 
census. We estimated the eﬀ ects of individual-level 
variables (sex and age) and community-level variables 
(urban or rural, screening season, screening during 
weekend, and assistance of village health workers) on 
the coverage of community screening with logistic 
regression adjusted for age and sex. We estimated 
linkage to care by dividing the number of individuals 
who visited the liver clinic by the number of HBsAg-
positive individuals identiﬁ ed at screening. We calculated 
the proportion eligible for treatment by dividing the 
number of individuals who fulﬁ lled the treatment 
criteria by the number of HBsAg-positive participants 
assessed at the clinic. We used logistic regression to 
estimate odds ratios (OR) for the factors associated with 
linkage to care and treatment eligibility. For the 
community screening, all of these estimates accounted 
for survey design (correlation within enumeration areas 
and stratiﬁ cation by urban or rural area) by use of the svy 
command in Stata 11.0. We did not apply ﬁ nite 
population correction because the sample size was small 
relative to the population size. The HBsAg prevalence, 
the proportion of HBsAg-positive individuals linked to 
care, and the proportion eligible for treatment among 
community screening participants were weighted for 
non-attendance to screening; the weighting was a 
reciprocal of the probability of screening coverage 
derived from a logistic regression with predictors (sex, 
age, and communities).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Between Dec 7, 2011, and Jan 24, 2014, all selected 
enumeration areas agreed to participate in the study and 
5980 (68·9%, 95% CI 65·0–72·4) of 8170 eligible people 
participated in the community screening (ﬁ gure 2). 
Median duration of screening per enumeration area was 
three days (IQR 3–5; range 2–8). The median age of 
participants was 43 years (IQR 35–55) and 2328 (38·9%) 
were men. Screening coverage varied between 
enumeration areas, from 48·9% to 95·1%, and was 
higher in women than in men (p<0·0001) and in older 
people than in younger people (p<0·0001; table 1). Of the 
community-level factors, after adjusting for age and sex, 
rural area (p=0·006), screening during the weekend 
(p=0·02), and assistance from village health workers 
(p=0·05) were associated with increased coverage 
(table 1). The two most common causes of non-attendance 
were absence due to work or travel (440 [36·8%] men and 
274 [27·6%] women) and perceived lack of beneﬁ t 
(284 [23·8%] men and 283 [28·5%] women; ﬁ gure 2).
Of the 5980 people screened in the communities, 
495 (8·8%, 95% CI 7·9–9·7) were identiﬁ ed as being 
HBsAg-positive. Prevalence of HBsAg varied between 
enumeration areas from 1·9% to 18·2%. Prevalence was 
higher in men (239 [10·5%, 8·9–12·1] of 2328 men) than 
in women (256 [7·6%] 6·5–8·7] of 3652 women; 
p=0·004), and in both sexes, prevalence decreased with 
age (p<0·0001 for men and p=0·004 for women; ﬁ gure 3) 
and was higher in urban (218 [8·9%] of 2511 individuals) 
than in rural areas (277 [8·2%] of 346 individuals), 
although the diﬀ erence was not signiﬁ cant after 
adjustment for age and sex.
Knowledge of HBV infection was extremely low in the 
communities; only two men (0·4%, 95% CI 0·0–6·1) out 
of 489 participants interviewed in 2013 had heard about 
HBV infection and had been tested for HBV in the past. 
None of the 54 HBsAg-positive individuals among these 
489 participants had been previously tested and knew 
their status.
Between Jan 1, and Dec 31, 2013, of the 6832 individuals 
who came for blood donation at the EFSTH (ﬁ gure 2), 
5559 (81·4%) were screened , of whom 5523 (99·3%) were 
men. Of these potential male donors, 159 were aged 
Total eligible 
(n=8170)
Attended p value Adjusted for age and sex
Odds ratio 
(95% CI)
p value
Individual-level factors
Sex
Male 3523 (43%) 2328 (60%) <0·0001 1·0 <0·0001
Female 4646 (57%) 3652 (76%) ·· 1·8 (1·5–2·1) ··
Age (years)
30–39 3259 (40%) 2397 (72%) <0·0001* 1·0 <0·0001* 
40–49 1822 (22%) 1456 (77%) ·· 1·3 (1·1–1·5) ··
50–59 1211 (15%) 988 (78%) ·· 1·5 (1·2–1·8) ··
≥60 1347 (16%) 1127 (81%) ·· 1·9 (1·6–2·2) ··
Community-level factors
Area
Urban 3785 (46%) 2511 (66%) 0·0001 1·0 0·006
Rural 4385 (54%) 3469 (79%) ·· 1·6 (1·2–2·2) ··
Season
Dry 6095 (75%) 4372 (68%) 0·5 1·0 0·7
Rainy 2075 (25%) 1608 (72%) ·· 1·1 (0·7–1·8) ··
Timing of screening
Weekdays only 5779 (71%) 4155 (67%) 0·02 1·0 0·02
Weekend 2391 (29%) 1825 (74%) ·· 1·4 (1·1–2·0) ··
Village health worker
Absent 5856 (72%) 4155 (68%) 0·005 1·0 0·05
Present 2314 (28%) 1825 (79%) ·· 1·6 (1·0–2·4) ··
Data are n (%) unless stated otherwise. Estimates accounted for survey design. *Test for trend. 
Table 1: Factors associated with screening coverage in the community 
See Online for appendix
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16–19 years, 2480 were aged 20–29 years, 1932 were aged 
30–39 years, 766 were aged 40–49 years, 175 were aged 
50–59 years, and 11 were aged 60 years or older. 1273 
(18·6%) individuals were not tested because of a shortage 
of HBsAg test kits.
721 (13·0%, 95% CI 12·1–13·9) of 5559 potential blood 
donors were HBsAg positive. Among men, prevalence 
was lowest in those aged 16–19 years (3·1%, 1·0–7·1) and 
highest in those aged 30–39 years (15·6%, 14·0–17·3; 
ﬁ gure 3). Age-speciﬁ c HBsAg prevalence in men screened 
at the blood bank did not diﬀ er compared with men from 
community-based screening. In women, there was no 
clear association between HBsAg prevalence and age, 
probably because the sample size was small (n=36). In a 
subset of potential donors (n=694) with available 
information, most (570 [82·1%]) were ﬁ rst-time donors 
and HBsAg positivity did not diﬀ er signiﬁ cantly between 
ﬁ rst-time and repeat donors after adjustment for age 
(data not shown).
Of the 495 HBsAg-positive individuals identiﬁ ed in 
community screening, 402 (81·3%, 95% CI 76·6–85·2) 
attended the liver clinic (ﬁ gure 2), and more of these 
people were from rural than from urban areas, although 
there was no association with age and sex (appendix 
p 1). Absence of symptoms and poor understanding of 
the disease were the main reasons for non-attendance 
among a subgroup of 25 HBV-infected individuals who 
did not attend the liver clinic and were able to be 
interviewed. Linkage to health care was poorer (300 
[41·6%, 38·0–45·3] of 721 HBsAg-positive individuals), 
in people screened at the blood bank than in those 
screened in the community (p<0·0001), possibly 
because of the unavailability of the coordinating nurse, 
especially during Ramadan and the last month of the 
year.
Most (617 [87·9%, 95% CI 85·3–90·1] of 702 individuals) 
of the HBsAg-positive individuals who attended the clinic 
after screening in both settings were classiﬁ ed as being 
inactive chronic carriers (table 2). HBeAg positivity was 
detected in 13 [3·3%] of 395 individuals from the 
community and 23 [7·9%] of 291 individuals from the 
blood bank for whom data were available.
Of the HBsAg-positive individuals screened  in the 
community with available data, 48 (12·2%) of 394 had 
alanine aminotransferase (ALT) levels over the upper 
limit of normal (40 IU/mL) and 41 (10·7%) of 382 had 
HBV DNA levels of 2000 IU/mL or more. After excluding 
11 participants without valid liver stiﬀ ness measurements, 
ten (2·6%) of 384 individuals had extensive ﬁ brosis (F3) 
and 11 (2·9%) had cirrhosis (F4). Co-infection with HIV, 
HCV, or HDV was detected in 3·3%, 1·0%, and 2·0% of 
participants, respectively. Among the HBV-infected 
individuals screened at the blood bank who had data 
available, 55 (18·8%) of 292 had ALT levels over the 
upper limit of normal (40 IU/mL), 38 (14·4%) of 264 had 
HBV DNA levels of 2000 IU/mL or more, and 50 (17·5%) 
of 286 had extensive ﬁ brosis or cirrhosis (≥F3).
47 (6·7%, 95% CI 5·1–8·8) of 702 HBV-infected 
individuals were eligible for treatment according to the 
EASL criteria (table 2; appendix p 3).19 More people 
screened at the blood bank (29 [9·7%, 6·8–13·6] of 
300 individuals) were eligible than were those screened in 
the community (18 [4·4%, 2·5–7·7] of 402 individuals; 
p=0·007). Use of the American Association for the Study 
of Liver Diseases criteria (appendix p 3)21 did not 
substantially change the number of people eligible for 
treatment (table 2). The diﬀ erence in treatment eligibility 
between the community and blood bank disappeared 
after we restricted the analysis to male participants 
(appendix p 2). Multivariable analysis showed that male 
sex (p=0·007) was associated with treatment eligibility 
(table 3). Age younger than 30 years also seemed to be 
associated with treatment eligibility, but the association 
was not signiﬁ cant (p=0·07). None of the eligible patients 
refused antiviral therapy. 12 months after the start of 
tenofovir therapy, 38 (80·9%) of 47 patients had high 
adherence scores, seven (14·9%) had medium adherence 
scores, and two (4·3%) had low adherence scores. After 
12 months of treatment, 43 (91·5%) of 47 patients 
achieved a virological response deﬁ ned as an undetectable 
HBV viral load, 38 (79·7%) had normal aminotransferase 
levels (<40 IU/mL), and nine (19%) had ALT levels over 
the upper limit of normal (40 IU/mL; median 46 IU/mL, 
IQR 43–62), with a baseline median ALT level of 49 IU/mL 
(IQR 34–104). No clinical or biological adverse events 
were observed after 12 months of treatment.
Figure 3: Prevalence of HBsAg positivity by age and sex in blood bank and 
community screening
Error bars represent 95% CIs. For blood bank screening, the analysis was 
restricted to males because of the small number of female blood donors (n=36). 
Error bars omitted for male donors aged 60 years or older because of small 
population (n=11). HBsAg=hepatitis B surface antigen.
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Discussion
Although able to prevent chronic infection,22 vaccination 
against HBV has been introduced only in the past 
20 years or so in sub-Saharan Africa. Coverage is less 
than ideal in many African countries, and even 
vaccination of neonates born to HBsAg-positive mothers 
has barely been implemented.5 Therefore, there is still a 
large legacy of chronically infected adults who will 
remain undiagnosed until they develop severe 
complications. The prevalence of HBsAg remains high 
in Gambian adults born after 1990, the year when 
The Gambia integrated the HBV vaccine into the national 
vaccination programme; in our study 3·1% of people 
screened at the blood bank aged 16–19 years were 
HBsAg positive, a higher proportion than that previously 
reported in a community-based study of the same age 
group (1·8%).23 Despite the implementation of HBV 
vaccination in The Gambia, the burden of HBV-related 
liver disease will probably remain high during the 
coming decades. It is therefore crucial to identify infected 
individuals through HBV screening and to manage them 
adequately to prevent liver complications. In The Gambia, 
HBV screening in the community by use of a rapid point-
of-care test was well accepted, with coverage of almost 
70%. This coverage is similar to that reported in other 
sub-Saharan African countries for community-based 
HIV (63% in rural Ugandan communities24 and 86% in 
semi-rural areas in Mozambique25) or malaria (64% in 
Zanzibar26) screening. Large-scale HBV screening might 
be challenging in sub-Saharan Africa because the disease 
is usually asymptomatic and awareness of HBV infection 
is poor in the general population and among health 
workers. Almost no participants enrolled in our study 
had previously been tested for HBV infection and were 
aware of their status. In fact, there is not even a term to 
deﬁ ne cirrhosis in Mandinka, the main local language in 
The Gambia.
In our study, a large proportion of HBsAg-positive 
individuals identiﬁ ed through community screening 
attended the liver clinic as advised and adherence to 
treatment was high; 81% of patients had good adherence 
1 year after the initiation of antiviral therapy, similar to 
that (77%) reported for antiretroviral HIV therapy 
elsewhere  in Africa.27 Additionally, 91·5% achieved a 
virological response at 1 year, which is in line with data 
from a European HBV cohort.28
By contrast with hospital-based studies, which are 
likely to overestimate the proportion of HBV carriers 
with advanced liver disease, 90·5% of chronically 
infected individuals from the community screening had 
inactive chronic hepatitis and only 4·4% needed antiviral 
therapy, supporting the feasibility of a community-based 
screen-and-treat intervention programme for HBV 
mono-infection in sub-Saharan Africa. Blood donors 
represent a diﬀ erent population to the community, being 
both younger and mostly male, with a higher proportion 
of individuals having detectable HBV viral loads. 
However, although the proportion of people eligible for 
treatment was higher at the blood bank than in the 
community, this diﬀ erence was not signiﬁ cant after 
adjustment for age and sex. This ﬁ nding is supported by 
a previous Ghanaian study of blood donors, which 
reported a similarly low proportion of individuals 
needing antiviral therapy based on ALT levels alone.8 By 
applying our ﬁ ndings to sub-Saharan Africa, we estimate 
that only 4 million people chronically infected with HBV 
(roughly 5% of the 80 million infected people) will 
require treatment: less than half the number of 
Community screening 
(n=402)
Blood bank screening 
(n=300)
p value
Age (years) 38 (33–47) 31 (27–35) <0·001
Male sex 193 (48·0%) 291 (97·0%) <0·001
Attended primary school 179/386 (46·4%) 185/223 (83·0%) <0·001
Body-mass index (kg/m²) 22·5 (20·0– 26·5) 22·4 (20·4–25·2) 0·9
Ever drank alcohol 28/397 (7·1%) 25/297 (8·4%) 0·5
Ever smoked cigarettes 125/387 (32·3%) 104/225 (46·2%) 0·001
Family history of hepatocellular 
carcinoma
16 (4·0%) 7 (2·3%) 0·2
Liver stiﬀ ness (kPa)* 4·7 (3·9–5·7) 5·9 (4·9–7·5) <0·001
METAVIR score*
F0–1 357 (93·0%) 229 (80·1%) <0·001
F2 6 (1·5%) 7 (2·5%)
F3 10 (2·6%) 29 (10·1%)
F4 11 (2·9%) 21 (7·3%)
Alanine aminotransferase (IU/L) 23 (18–30) 27 (21–36) <0·001
Alanine aminotransferase ≥40 IU/mL 48/394 (12·2%) 55/292 (18·8%) 0·02
Aspartate aminotransferase (IU/L) 29 (24–34) 32 (27–39) <0·001
γ-glutamyl transferase (IU/L) 25 (19–34) 28 (22–39) <0·001
Alkaline phosphatase (IU/L) 90 (76–112) 81 (68–97) <0·001
Platelets (10⁹ cells per L) 203 (159–253) 170 (142–205) <0·001
HBeAg positive 13/395 (3·3%) 23/291 (7·9%) 0·007
Undetectable HBV DNA 188/382 (49·2%) 107/264 (40·5%) 0·03
HBV DNA (IU/L)† 297 (134–1577) 350 (118–1884) 0·8
HBV DNA ≥2000 IU/mL 41/382 (10·7%) 38/264 (14·4%) 0·2
HBV genotype 0·6
A 28/167 (16·8%) 15/104 (14·4%)
E 139/167 (83·2%) 89/104 (85·6%)
HIV positive 13/398 (3·3%) NA§ NA
HDV positive 8/394 (2·0%) 1/292 (0·3%) 0·06
HCV positive 4/394 (1·0%) 5/280 (1·8%) 0·4
Inactive chronic carrier 364 (90·5%) 253 (84·3%) 0·01
Eligible for EASL criteria 18 (4·4%)‡ 29 (9·7%) 0·007
Eligible for AASLD criteria 14 (4·1%)‡ 21 (7·0%) 0·03
Data are n (%), n/N (%), or median (IQR). Some characteristics have diﬀ erent denominators because of missing data. 
NA=not applicable. HBeAg=hepatitis B envelope antigen. HBV=hepatitis B virus. HCV=hepatitis C virus. HDV=hepatitis 
delta virus. EASL=European Association for the Study of the Liver. AASLD=American Association for the Study of Liver 
Diseases. *Excludes 18 participants without measurement, seven  with transient elastography measurement failure, 
and seven with unreliable measurements. †Excludes 295 participants with undetectable HBV DNA. ‡Percentages were 
calculated with weights for stratiﬁ cation and non-attendance to the screening and liver clinic. §The individuals who 
tested positive for HIV were not referred to our liver clinic, but were instead referred to the HIV clinic.
Table 2: Clinical and biological characteristics of the HBV-infected participants from the community and 
the blood bank screening 
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HIV-infected patients in need of antiretroviral therapy in 
sub-Saharan Africa.
Screening coverage in the community was lower in 
young men than in women or older individuals, which is 
consistent with observations from community screening 
for HIV in sub-Saharan Africa. Low coverage in young 
men is problematic because they are more likely to be 
infected with HBV and in need of treatment. About a third 
(36·8%) of men who did not attend our community 
screening were absent because of work or travel during 
the screening session, which suggests that screening 
during weekends might increase coverage in this group. 
By contrast, many young men came to donate their blood 
and accepted screening for HBV. However, less than half 
of those individuals identiﬁ ed as being HBsAg positive 
attended the liver clinic. In sub-Saharan Africa, care and 
treatment of deferred donors with HBV infection need to 
be improved, because blood banks oﬀ er an opportunity to 
reach this high-risk and diﬃ  cult-to-manage group. 
Nevertheless, only a small proportion of young men 
donate blood, meaning that the overall population covered 
would remain small.
Notably, we found that 18·6% of people attending the 
blood bank were not tested for HBV because of a shortage 
of diagnostic kits. This concurs with the ﬁ ndings of the 
2012 WHO report on blood safety,29 which showed that 
24% of blood banks do not systematically screen for 
transfusion-transmissible infections in resource-limited 
countries, with irregular supply of test kits cited as being 
the main barrier.29
Our study has some limitations. First, although the study 
implementation was adapted to real-life local conditions, it 
had the support of well-trained ﬁ eldworkers from a well-
known research institution (the MRC Unit, The Gambia). 
Consequently, screening coverage and linkage to care 
could have been overestimated with respect to real-life 
implementation. Second, we might have underestimated 
the prevalence of HBsAg by using a rapid immuno-
chromatography test, which has a sensitivity of 89–96% 
with ELISA as a reference. False-negative results in such 
tests are reported to be associated with low HBsAg levels 
and inactive disease state,12,30 suggesting that the clinical 
impact of their moderate sensitivity is negligible since the 
people not identiﬁ ed would not need treatment. We noted 
a signiﬁ cant decrease in HBsAg prevalence as age 
increased, and this might be explained by false-negative 
results in older people with chronic infection who tend to 
have low HBsAg levels. Nevertheless, this trend has been 
consistently reported in population-based serosurveys in 
sub-Saharan Africa22,31,32 and is often attributed to 
spontaneous seroclearance of HBsAg and higher mortality 
in people with chronic HBV infection than in people 
without HBV infection. Third, to quantify HBV DNA, we 
used an in-house qPCR assay that had a limit of detection 
slightly higher than that of commercial assays (50 IU/L vs 
<20 IU/L), which might have overestimated the proportion 
of participants with undetectable HBV DNA. Fourth, in 
accordance with the recommendations of the scientiﬁ c 
committee, we targeted our screening in the community at 
individuals aged 30 years or older, because younger age 
groups would have beneﬁ ted from the high coverage of 
HBV infant vaccination in The Gambia (estimated at 
>90%).3 Nevertheless, the results of our screening in young 
people at the blood bank show that HBV screening 
remains important in Gambians younger than 30 years, 
with a high proportion of people in this age group needing 
antiviral therapy. Fifth, we might have underestimated 
All HBsAg-positive 
individuals (n=702)
Eligible for 
therapy (%)
p value Adjusted for age and sex
Odds ratio (95% CI) p value
Sex
Female 218 4 (1·8%) 0·001 1·00 0·007
Male 484 43 (8·9%) 4·35 (1·50–12·58)
Age (years)
17–29 130 16 (12·3%) 0·01* 1·00 0·07*
30–39 350 22 (6·3%) 0·65 (0·33–1·30)
≥40 220 9 (4·1%) 0·45 (0·19–1·07)
Primary school
Never 245 10 (4·1%) 0·01 1·00 0·4
Ever 364 34 (9·3%) 1·36 (0·62–3·02)
BMI (kg/m²)
<30 638 47 (7·4%) 0·05 1·00 NA
≥30 51 0 NA
Alcohol
Never 641 43 (6·7%) 0·8 1·00 0·9
Ever 53 4 (7·6%) 0·93 (0·32–2·74)
Cigarettes
Never 383 24 (6·3%) 0·2 1·00 0·9
Ever 229 21 (9·2%) 0·98 (0·51–1·88)
Family history of hepatocellular carcinoma
Absent 679 44 (6·5%) 0·2 1·00 0·1
Present 23 3 (13·0%) 2·74 (0·75–9·95)
HIV
Negative 682 46 (6·7%) 0·9 1·00 0·6
Positive 16 1 (6·3%) 1·73 (0·21–14·24)
HDV
Negative 677 47 (6·9%) 0·4 1·00 NA
Positive 9 0 NA
HCV
Negative 665 44 (6·6%) 0·6 1·00 0·6
Positive 9 1 (11·1%) 1·88 (0·22–15·98)
Genotype
E 228 26 (11·4%) 0·6 1·00 0·6
A 43 6 (14·0%) 1·27 (0·48–3·37)
Screening settings
Community 402 18 (4·5%) 0·007 1·00 1·0
Blood bank 300 29 (9·7%) 1·02 (0·47–2·22)
HBsAg=hepatitis B surface antigen. HCV=hepatitis C virus. HDV=hepatitis D virus. BMI=body-mass index. 
NA=not applicable. *Test for trend.
Table 3: Factors associated with eligibility for antiviral treatment 
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HBsAg prevalence at the blood bank because we were 
unable to exclude repeat donors from the analysis. 
However, the eﬀ ect should be minimal because HBsAg 
screening was only started at blood banks in 2011 and 
frequent shortages of testing kits have occurred. In a 
subset of participants with available information about 
previous blood donation, HBsAg prevalence was similar 
between ﬁ rst-time and repeat donors. Finally, we assessed 
treatment eligibility at a single timepoint, but the 
longitudinal follow-up of our cohort is likely to identify 
additional eligible patients. We will address this question 
in the future.
In high-income countries, community-based screening 
for viral hepatitis has rarely been done without 
assessment of the proportion of infected individuals in 
need of treatment.33,34 Consequently, our study provides 
original and important data about need for treatment, 
particularly in the general population, which will be 
useful for clinicians as well as policy makers.
According to the Wilson and Jungner WHO screening 
criteria,11 our results conﬁ rmed that HBV mass screening 
is justiﬁ ed in The Gambia (appendix p 4) and our 
screening strategy in the community is cost-eﬀ ective, as 
reported in a companion paper in this journal.35 Whether 
such an intervention should be incorporated within 
other national screening programmes (eg, for HIV or 
non-communicable diseases) should be investigated in 
the future.
In conclusion, HBV screen-and-treat programme 
targeting the general population is a feasible and realistic 
public health intervention in The Gambia. Such an 
intervention deserves to be assessed on a larger scale in 
sub-Saharan Africa and in other resource-limited 
countries, with eventual integration into international 
and national guidelines to ﬁ ght against the burden of 
HBV infection in endemic areas.
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